IDEAYA CEO granted 600,000 stock options

IDEAYA Biosciences President and CEO Yujiro Hata received a grant of stock options reported as of January 30, 2026.

Accepted by SEC EDGAR 02/02/2026 - 07:58 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

IDEAYA Biosciences President and CEO Yujiro Hata received a grant of stock options reported as of January 30, 2026. The award covers 600,000 options to buy IDEAYA common stock at an exercise price of $32.19 per share.

According to the vesting terms, 25% of the options vest on the first anniversary of January 1, 2026, and the remaining portion vests in equal monthly installments over the following three years, so the grant becomes fully vested on the fourth anniversary of that date.

Insider Trade Summary

Grant/Award: 600,000 shares

Grant/Award 1 txn

Insider Hata Yujiro S

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	600,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 600,000 contracts (Direct)

Footnotes (1)

1. F1. 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IDEAYA Biosciences (IDYA) disclose about its CEO in this Form 4?

IDEAYA Biosciences reported a stock option grant to its President and CEO, Yujiro Hata. The filing shows an award of 600,000 stock options, documenting the exercise price, vesting schedule, and that the options are held directly following the reported transaction.

How many stock options did IDEAYA CEO Yujiro Hata receive in the latest IDYA Form 4?

Yujiro Hata received 600,000 stock options relating to IDEAYA Biosciences common stock. The options are reported as directly owned following the transaction, and they give the right to purchase an equal number of IDEAYA common shares if exercised under the specified terms.

What is the exercise price of the IDEAYA (IDYA) stock options granted to the CEO?

The stock options granted to the CEO have an exercise price of $32.19 per share. This means each option allows the purchase of one IDEAYA common share at $32.19, subject to the vesting schedule described for this award in the Form 4 filing.

How do the IDEAYA CEO stock options reported on Form 4 vest over time?

Twenty-five percent of the options vest one year after January 1, 2026. The remaining options vest in equal monthly installments over the next three years, so all 600,000 options become fully vested and exercisable on the fourth anniversary of that January 1, 2026 vesting commencement date.

When will the IDEAYA (IDYA) CEO’s stock options be fully vested and exercisable?

The options will be fully vested and exercisable on the fourth anniversary of January 1, 2026. This schedule reflects 25% vesting after the first year from that date and the balance vesting monthly over the following three years, as detailed in the Form 4 footnote.

Are the IDEAYA CEO stock options reported on this Form 4 held directly or indirectly?

The Form 4 lists the 600,000 stock options as directly owned by the reporting person. The ownership form column identifies the derivative securities as “D” for direct ownership, with no indication of indirect holding through another entity or account in the provided disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hata Yujiro S

(Last) (First) (Middle)

C/O IDEAYA BIOSCIENCES, INC.

5000 SHORELINE COURT, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IDEAYA Biosciences, Inc. [ IDYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$32.19	01/30/2026		A		600,000		(1)	01/30/2036	Common Stock	600,000	$0	600,000	D

Explanation of Responses:

1. 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

	/s/ Joshua Bleharski, as Attorney-in-Fact for Yujiro Hata	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.